While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

Reaffirmed FY25 NPATA guidance of $3.2 billion to $3.3 billion at constant currency, representing year-on-year growth of ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

Read full article: Want to bring low-spend January into the rest of the year? Start by owning your Microsoft apps FILE - ...